@article {2255, title = {Mozart K488 Addition Can Improve Depressive-Like Behavior in Rats: In Search of Better Management}, journal = {Pharmacognosy Journal}, volume = {16}, year = {2024}, month = {April 2024}, pages = {348-354}, type = {Research Article}, chapter = {348}, abstract = {

Background: Fluoxetine is one of the medications used for the treatment of depression with several benefits, but some patients have a poor response to the drug. Several studies reported the use of Mozart music (K448) as an alternative therapy for treating the condition, yet the combination of Mozart and fluoxetine remains underexplored. In light of this, this study aims to assess the impact of combined fluoxetine and Mozart (K448) therapy on depressive-like behavior and associated hormonal changes in a rodent model subjected to Chronic Unpredictable Mild Stress (CUMS) conditions. Materials and Methods: The depression-induced animal model received one of these three specified treatments: fluoxetine (F), Mozart (M), or a combination of fluoxetine and Mozart (F+M). The depressive-like behavior was assessed using a 24-hour sucrose preference test (SPT). Additionally, after 21 days of treatment, plasma corticosterone levels and hippocampal melatonin levels were assessed. Statistical analysis using either ANOVA or Kruskal-Wallis tests was then performed. Results: The fluoxetine-Mozart group had higher SPT compared to CUMS group. However, they do not have a better result compared to other groups in terms of corticosterone and melatonin levels with values of respectively. Conclusion: The combined therapy of fluoxetine and Mozart improved depressive-like behavior.

}, keywords = {Corticosterone, Depressive-like behavior, Fluoxetine, Hippocampus, Melatonin, Mozart}, doi = {10.5530/pj.2024.16.53}, author = {Lisa Pangemanan and Irwanto and Margarita M. Maramis} } @article {2002, title = {The Antidepressant Effect of Fluoxetine and Mozart K448 Combination Therapy on Hippocampal Serotonin and BDNF Levels}, journal = {Pharmacognosy Journal}, volume = {15}, year = {2023}, month = {April 2023}, pages = {325-328}, type = {Original Article }, chapter = {325}, abstract = {

Despite the use of fluoxetine as a first-line therapy, some patients do not show a good therapeutic effect. Effective antidepressant therapy will reverse the low serotonin and BDNF levels found in depression. Mozart K. 448 was reported to yield a good therapeutic effect for depression. Based on findings, the combination of Mozart K. 448 and fluoxetine as a therapy for depression is very rare. Therefore, this study aimed to determine the effect of the combined therapy of fluoxetine and Mozart K. 448 on hippocampal serotonin and BDNF levels in an animal model of depression under CUMS conditions. In this study, the animal model of depression was administered three different treatments, i.e. fluoxetine, Mozart, or fluoxetine-Mozart combined therapy, respectively. Hippocampal serotonin and BDNF levels were assessed after 21 days of treatment. Statistical analysis was then carried out using T-test or Mann-Whitney test and ANOVA or Kruskal-Wallis. The fluoxetine-Mozart group has higher BDNF levels, but lower serotonin levels compared to other groups with values of 1,694{\textpm}0.215 and 44,533{\textpm}3,275, respectively.

}, keywords = {BDNF, Fluoxetine, Hippocampus, Mozart, Serotonin}, doi = {10.5530/pj.2023.15.48}, author = {Lisa Pangemanan and Irwanto Irwanto and Margarita M. Maramis} }